Objective: Blood biomarkers of neuronal injury such as neurofilament light (NfL) show
promise to improve diagnosis of neurodegenerative disorders and distinguish …

The overlapping symptoms of behavioural variant frontotemporal dementia (bvFTD) and
primary psychiatric disorders (such as depressive disorder, schizophrenia spectrum, and …

Introduction Many patients with cognitive and neuropsychiatric symptoms face diagnostic
delay and misdiagnosis. We investigated whether cerebrospinal fluid (CSF) neurofilament …

Background: Distinguishing behavioural variant frontotemporal dementia (bvFTD) from non-
neurodegenerative 'non-progressor'mimics of frontal lobe dysfunction, can be one of the …

Due to the significant clinical overlap between frontotemporal lobar degeneration (FTLD)
spectrum disorders and late-onset primary psychiatric disorders (PPD), diagnostic …

Objective To determine the association of serum neurofilament light chain (NfL) with
functional deterioration and brain atrophy during follow-up of patients with behavioral variant …

Objective: People with neuropsychiatric symptoms often experience delay in accurate
diagnosis. Although cerebrospinal fluid neurofilament light (CSF NfL) shows promise in …

Background: Frontotemporal dementia (FTD) syndromes, mimics, phenocopy (phFTD), and
slowly progressive behavioral variant FTD (bvFTD) can be difficult to distinguish clinically …

Objective: Neurofilament light has shown promise as a biomarker for diagnosis, staging and
prognosis in a wide range of neurological and neurodegenerative disorders. This study …

Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for
neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as …